TD Cowen cuts Orthofix Medical stock price target on supply issues

TD Cowen reduced its price target for Orthofix Medical (OFIX) to $9 from $12, citing Q3 results that missed expectations and supply issues. The stock has fallen 48% year-to-date. OFIX revised its 2026 guidance lower due to Q4 challenges. Despite a Q3 earnings beat, revenue missed forecasts, leading to a negative market reaction. Analysts expect profitability in 2024 with earnings of $0.69 per share.

Original reporting
Published Nov 10, 2026, 2:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$OFIX
Bearish
high confidence
Mentioned
$OFIX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OFIXBearishMed
01

Why it matters

Analyst target reduction may accelerate the stock's recent 10% weekly decline, but fair‑value estimates imply upside potential if issues resolve.

02

Market read

The target cut provides fresh actionable insight for traders holding or considering OFIX.

03

What to watch

Potential profitability this year and a possible rebound if supply constraints ease.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Orthofix Medical reported Q3 miss and supply constraints in its spine product line, prompting a guidance downgrade for FY 2026.

Company-level read

Ticker impact

$OFIXBearishHigh confidence
Context

TD Cowen lowered its price target on Orthofix Medical to $9 from $12 following Q3 results and revised FY guidance.

Expected impact

likely downside as the market prices in the lower target and guidance revision

Evidence & confidence

The new $9 target is substantially below the prior $12 and below current trading price, indicating potential further sell pressure.

Market effects

Spine medical device sector may face broader scrutiny as supply issues are noted as not unique to Orthofix.

US small‑cap healthcare segment could see modest pullback.

Limited; impact confined to niche medical device investors.

Counterpoint

Fair value models still show a $12.30 valuation, suggesting the price target cut may be overly pessimistic.

Key entities

  • TD Cowen

    Equity research firm that cut the price target.

  • Orthofix Medical

    Medical device maker focused on spine products.

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte